A Festschrift in Honor of Edward M. Messing, MD, FACS

Affiliations

¹ University of Rochester Medical Center, Rochester, NY, USA.
² Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA.
³ Roswell Cancer Institute, Buffalo, NY, USA.
⁴ Cedars Sinai Medical Center, Los Angeles, CA, USA.
⁵ UF Health Proton Therapy Institute, Gainesville, FL, USA.
⁶ Johns Hopkins Greenberg Bladder Cancer Institute, Baltimore, MD, USA.
⁷ CHU de Quebec-Hotel-Dieu de Quebec, Quebec, QC, Canada.
⁸ MD Anderson Cancer Center, Houston, TX, USA.
⁹ State University of New York at Buffalo, Buffalo, NY, USA.
¹⁰ UT Southwestern Medical Center at Dallas, Dallas, TX, USA.
¹¹ University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.
¹² SUNY Upstate Medical University, Syracuse, NY, USA.
¹³ Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH, USA.
¹⁴ UC San Diego, San Diego, CA, USA.
¹⁵ Lund University, Malmo, Sweden.
¹⁶ Memorial Healthcare System, Aventura, FL, USA.
¹⁷ Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, USA.
¹⁸ Lifespan Cancer Institute, Providence, RI, USA.
¹⁹ UT Health Science Center San Antonio, San Antonio, TX, USA.
²⁰ Baylor College of Medicine Medical Center, Houston, TX, USA.
²¹ University of Michigan Medical School, Ann Arbor, MI, USA.
²² Mt. Sinai Medical Center, New York, NY, USA.
²³ Virginia Commonwealth University, Fairfax, VA, USA.

Jean V Joseph et al. Bladder Cancer. 2018.

. 2018 Oct 3;4(Suppl 1):S1-S43.

doi: 10.3233/BLC-189037.

¹ University of Rochester Medical Center, Rochester, NY, USA.
² Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA.
³ Roswell Cancer Institute, Buffalo, NY, USA.
⁴ Cedars Sinai Medical Center, Los Angeles, CA, USA.
⁵ UF Health Proton Therapy Institute, Gainesville, FL, USA.
⁶ Johns Hopkins Greenberg Bladder Cancer Institute, Baltimore, MD, USA.
⁷ CHU de Quebec-Hotel-Dieu de Quebec, Quebec, QC, Canada.
⁸ MD Anderson Cancer Center, Houston, TX, USA.
⁹ State University of New York at Buffalo, Buffalo, NY, USA.
¹⁰ UT Southwestern Medical Center at Dallas, Dallas, TX, USA.
¹¹ University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.
¹² SUNY Upstate Medical University, Syracuse, NY, USA.
¹³ Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH, USA.
¹⁴ UC San Diego, San Diego, CA, USA.
¹⁵ Lund University, Malmo, Sweden.
¹⁶ Memorial Healthcare System, Aventura, FL, USA.
¹⁷ Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, USA.
¹⁸ Lifespan Cancer Institute, Providence, RI, USA.
¹⁹ UT Health Science Center San Antonio, San Antonio, TX, USA.
²⁰ Baylor College of Medicine Medical Center, Houston, TX, USA.
²¹ University of Michigan Medical School, Ann Arbor, MI, USA.
²² Mt. Sinai Medical Center, New York, NY, USA.
²³ Virginia Commonwealth University, Fairfax, VA, USA.

No abstract available

Figures

1. Institute NC: Cancer stat facts: Bladder cancer. Surveillance, Epidemiology, and End Results Program. 2018.
1. Stein JP, Lieskovsky G, Cote R, et al. Radical cystectomy in the treatment of invasive bladder cancer: Long-term results in 1,054 patients. Journal of Clinical Oncology. 2001;19:666–75. - PubMed
1. von der Maase H, Hansen SW, Roberts JT, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: Results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol. 2000;18:3068–77. - PubMed
1. Galsky MD, Hahn NM, Rosenberg J, et al. A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy. The Lancet Oncology. 2011;12:211–4. - PubMed
1. Balar AV, Castellano D, O’Donnell PH, et al. First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): A multicentre, single-arm, phase 2 study. Lancet Oncol. 2017;18:1483–92. - PubMed